Unidad de Gastroenterología, Hospital General Universitario de Alicante, Alicante, Spain.
Gastroenterology. 2013 May;144(5):926-932.e1; quiz e13-4. doi: 10.1053/j.gastro.2013.01.044. Epub 2013 Jan 24.
BACKGROUND & AIMS: Colorectal cancers (CRCs) with microsatellite instability (MSI) and a mismatch repair (MMR) immunohistochemical deficit without hypermethylation of the MLH1 promoter are likely to be caused by Lynch syndrome. Some patients with these cancers have not been found to have pathogenic germline mutations and are considered to have Lynch-like syndrome (LLS). The aim of this study was to determine the risk of cancer in families of patients with LLS.
We studied a population-based cohort of 1705 consecutive patients, performing MSI tests and immunohistochemical analyses of MMR proteins. Patients were diagnosed with Lynch syndrome when they were found to have pathogenic germline mutations. Patients with MSI and loss of MSH2 and/or MSH6 expression, isolated loss of PMS2 or loss of MLH1 without MLH1 promoter hypermethylation, and no pathogenic mutation were considered to have LLS. The clinical characteristics of patients and the age- and sex-adjusted standardized incidence ratios (SIRs) of cancer in families were compared between groups.
The incidence of CRC was significantly lower in families of patients with LLS than in families with confirmed cases of Lynch syndrome (SIR for Lynch syndrome, 6.04; 95% confidence interval [CI], 3.58-9.54; SIR for LLS, 2.12; 95% CI, 1.16-3.56; P < .001). However, the incidence of CRC was higher in families of patients with LLS than in families with sporadic CRC (SIR for sporadic CRC, 0.48; 95% CI, 0.27-0.79; P < .001).
The risk of cancer in families with LLS is lower that of families with Lynch syndrome but higher than that of families with sporadic CRC. These results confirm the need for special screening and surveillance strategies for these patients and their relatives.
微卫星不稳定(MSI)和错配修复(MMR)免疫组织化学缺陷而 MLH1 启动子无甲基化的结直肠癌(CRC)可能由林奇综合征引起。一些患有这些癌症的患者未发现致病性种系突变,被认为患有林奇样综合征(LLS)。本研究旨在确定 LLS 患者家族的癌症风险。
我们研究了一个基于人群的 1705 例连续患者队列,进行了 MSI 测试和 MMR 蛋白的免疫组织化学分析。当发现致病性种系突变时,患者被诊断为林奇综合征。MSI 且 MSH2 和/或 MSH6 表达缺失、PMS2 孤立缺失或 MLH1 缺失而无 MLH1 启动子甲基化、无致病性突变的患者被认为患有 LLS。比较了各组患者的临床特征和家族中癌症的年龄和性别调整标准化发病比(SIR)。
与确诊的林奇综合征家族相比,LLS 患者家族的 CRC 发生率显著降低(林奇综合征的 SIR 为 6.04;95%置信区间 [CI],3.58-9.54;LLS 的 SIR 为 2.12;95%CI,1.16-3.56;P<.001)。然而,LLS 患者家族的 CRC 发生率高于散发性 CRC 家族(散发性 CRC 的 SIR 为 0.48;95%CI,0.27-0.79;P<.001)。
LLS 家族的癌症风险低于林奇综合征家族,但高于散发性 CRC 家族。这些结果证实了这些患者及其亲属需要特殊的筛查和监测策略。